Ability Pharmaceuticals (Spain)

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells

Pau Muñoz‐Guardiola, Josefina Casas, Elisabet Megías‐Roda et al. · Autophagy · 2020 · 106 citations · Full text

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer

Isidre Felip, Cristian P. Moiola, Cristina Megino‐Luque et al. · Gynecologic Oncology · 2019 · 39 citations

Tumor Biology, Cell Autophagy, Oncology +11

The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival

Nora Diéguez-Martínez, Sergio Espinosa-Gil, Guillermo Yoldi et al. · Cellular and Molecular Life Sciences · 2022 · 29 citations · Full text

The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer

Anna López‐Plana, Patricia Fernández‐Nogueira, Pau Muñoz‐Guardiola et al. · International Journal of Cancer · 2020 · 24 citations · Full text

Oncology, Chemoprevention Strategy, Tumor Microenvironment +13

A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours

Laura Vidal, Iván Victoria, Lydia Gaba et al. · European Journal of Cancer · 2021 · 24 citations

Hematological Malignancy, Cell Autophagy, Medicine +10